MM - 263
Reduced-Frequency Dosing of FDA-Approved Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma: A Systematic Review of Maintaining Efficacy While Reducing Infection-Related Toxicity
Mahboob Younus Shaik
Poster Presenter: Mahboob Younus Shaik
